文献速递腹部技术与安全CT

可切除胰体/尾腺癌术后复发预测:基于CT列线图的新型风险分层方法

Prediction of postoperative recurrence in resectable pancreatic body/tail adenocarcinoma: a novel risk stratification approach using a CT-based nomogram.
PubMed 文献 · Eur Radiol · 2023-08-25

回顾性纳入258例可切除胰体/尾腺癌患者(开发队列172例、验证队列86例),基于静脉期肿瘤密度、肿瘤坏死、邻近器官侵犯、脾静脉侵犯及肠系膜上静脉/门静脉接触5个CT特征构建列线图预测无复发生存。验证队列C指数0.65(95%CI 0.58-0.73),高于第8版AJCC病理分期系统;0.5、1、2年复发预测AUC分别为0.66、0.71、0.72,高风险组1年复发概率0.73、低风险组0.43。

要点

  • 静脉期肿瘤密度、肿瘤坏死、邻近器官侵犯、脾静脉侵犯、肠系膜上静脉/门静脉接触为复发相关CT特征。
  • 基于上述5个CT特征的列线图验证队列C指数0.65,高于第8版AJCC分期系统。
  • 列线图将患者分为高风险组(1年复发概率0.73)与低风险组(0.43)。

核心结论

  • 所提出的列线图可在术前对可切除胰体/尾腺癌患者进行准确的复发风险分层,可能有助于临床决策。

研究设计与样本

  • 回顾性纳入258例接受 upfront 手术的可切除胰体/尾腺癌患者(开发队列172例、验证队列86例),分析临床与CT特征,采用逐步Cox比例风险分析构建预测无复发生存的列线图,并与第8版AJCC病理分期系统比较。

关键影像表现/征象

  • 静脉期肿瘤密度、肿瘤坏死、邻近器官侵犯、脾静脉侵犯及肠系膜上静脉/门静脉接触被识别为预测复发的CT特征并用于构建列线图。

诊断标准与关键数值

  • 验证队列中基于CT的列线图C指数为0.65(95%CI 0.58-0.73),高于第8版AJCC分期系统。
  • 列线图预测0.5年、1年、2年复发的AUC分别为0.66、0.71、0.72。
  • 患者分为高风险组与低风险组,1年复发概率分别为0.73与0.43。

临床应用与阅片要点

  • 所提出的列线图基于易于获取的CT特征,可能作为有效且简便的工具,进一步对胰体/尾腺癌患者的复发风险进行分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To identify prognostic CT features that predict recurrence in patients with resectable pancreatic body/tail adenocarcinoma (PBTA) and construct a CT-based nomogram for preoperative risk stratification.

METHODS: A total of 258 patients with resectable PBTA who underwent upfront surgery were retrospectively enrolled (development cohort, n = 172; validation cohort, n = 86), and their clinical and CT features were analyzed. Stepwise Cox proportional hazard analysis was performed to identify prognostic features and construct a predictive nomogram for recurrence-free survival (RFS). The prognostic performance of the CT-based nomogram was validated and compared to the 8th American Joint Committee on Cancer (AJCC) pathological staging system.

RESULTS: In the development cohort, the following five CT features for predicting recurrence were identified to construct the nomogram: tumor density in the venous phase, tumor necrosis, adjacent organ invasion, splenic vein invasion, and superior mesenteric vein/portal vein abutment. In the validation cohort, the CT-based nomogram showed a concordance index of 0.65 (95% confidence interval: 0.58-0.73), which was higher than the 8th AJCC staging system. The area under the curves of the nomogram for predicting recurrence at 0.5, 1, and 2 years were 0.66, 0.71, and 0.72, respectively. Patients were categorized into high- and low-risk groups with 1-year recurrence probabilities of 0.73 and 0.43, respectively.

CONCLUSIONS: The proposed nomogram provided accurate recurrence risk stratification for patients with resectable PBTA in a preoperative setting and may be used to facilitate clinical decision-making.

CLINICAL RELEVANCE STATEMENT: The proposed CT-based nomogram, based on easily available CT features, may serve as an effective and convenient tool for stratifying further the recurrence risk of patients with pancreatic body/tail adenocarcinoma.

KEY POINTS: • The CT-based nomogram, incorporating five commonly used CT features, successfully preoperatively stratified patients with resectable PBTA into distinct prognosis groups. • Tumor density in the venous phase, tumor necrosis, splenic vein invasion, adjacent organ invasion, and superior mesenteric vein/portal vein abutment were associated with RFS in patients with resectable PBTA. • The CT-based nomogram exhibited better predictive performance for recurrence than the 8th AJCC staging system.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Xie T, Xie X, Liu W, et al. Prediction of postoperative recurrence in resectable pancreatic body/tail adenocarcinoma: a novel risk stratification approach using a CT-based nomogram. Eur Radiol. 2023. PMID: 37624415. doi:10.1007/s00330-023-10047-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。